RAMM Pharma Statistics
Total Valuation
RAMM Pharma has a market cap or net worth of CAD 1.19 million. The enterprise value is 1.12 million.
| Market Cap | 1.19M |
| Enterprise Value | 1.12M |
Important Dates
The next estimated earnings date is Friday, September 25, 2026.
| Earnings Date | Sep 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RAMM Pharma has 119.39 million shares outstanding.
| Current Share Class | 119.39M |
| Shares Outstanding | 119.39M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 31.43% |
| Owned by Institutions (%) | 0.01% |
| Float | 81.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.63 |
| PB Ratio | 0.27 |
| P/TBV Ratio | 0.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.47, with a Debt / Equity ratio of 0.01.
| Current Ratio | 0.47 |
| Quick Ratio | 0.20 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.76 |
Financial Efficiency
Return on equity (ROE) is -102.05% and return on invested capital (ROIC) is -30.80%.
| Return on Equity (ROE) | -102.05% |
| Return on Assets (ROA) | -23.31% |
| Return on Invested Capital (ROIC) | -30.80% |
| Return on Capital Employed (ROCE) | -97.33% |
| Weighted Average Cost of Capital (WACC) | 22.43% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0.86 |
Taxes
In the past 12 months, RAMM Pharma has paid 10,699 in taxes.
| Income Tax | 10,699 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.59 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.03 |
| Relative Strength Index (RSI) | 39.99 |
| Average Volume (20 Days) | 85,297 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RAMM Pharma had revenue of CAD 1.89 million and -8.72 million in losses. Loss per share was -0.07.
| Revenue | 1.89M |
| Gross Profit | 736,608 |
| Operating Income | -4.23M |
| Pretax Income | -8.70M |
| Net Income | -8.72M |
| EBITDA | -3.90M |
| EBIT | -4.23M |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 119,546 in cash and 44,171 in debt, with a net cash position of 75,375 or 0.00 per share.
| Cash & Cash Equivalents | 119,546 |
| Total Debt | 44,171 |
| Net Cash | 75,375 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 4.35M |
| Book Value Per Share | 0.04 |
| Working Capital | -1.46M |
Cash Flow
| Operating Cash Flow | -1.60M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 328,597 |
| Net Borrowing | -69,800 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 38.93% |
| Operating Margin | -223.55% |
| Pretax Margin | -460.07% |
| Profit Margin | n/a |
| EBITDA Margin | -206.18% |
| EBIT Margin | -223.55% |
| FCF Margin | n/a |
Dividends & Yields
RAMM Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -730.02% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RAMM Pharma has an Altman Z-Score of -16.07 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.07 |
| Piotroski F-Score | 2 |